Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. on April 21, 2026. The filing serves to disclose Regulation FD information and other material events related to the company's preclinical research programs.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational milestones rather than financial performance data.
Material Changes and Events
- Preclinical Data Announcement: On April 21, 2026, the company issued a press release announcing preclinical data for multiple programs presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
- Key Programs: The data covers the SMARCA2 selective inhibitor FHD-909 and selective CBP, EP300, and ARID1B degrader programs.
- Investor Presentation: The company furnished an investor presentation dated April 2026 as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding clinical trials, pre-clinical programs, and product candidates. Management notes that actual results may differ materially from expectations due to inherent uncertainties, including regulatory conditions and clinical trial risks. The company refers investors to the "Risk Factors" section of its Annual Report on Form 10-K for the year ended December 31, 2025, for a detailed discussion of these risks.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.2) for specific details on the preclinical data for FHD-909 and degrader programs.
- Examine the investor presentation (Exhibit 99.1) for updated timelines and strategic priorities.
- Consult the most recent Form 10-K (filed for the year ended December 31, 2025) for current financial position, cash runway, and comprehensive risk factors.
- Verify the status of the SMARCA2 selective inhibitor and degrader programs in subsequent regulatory filings.